Currently, nonsteroidal MRAs are undergoing assessment for their efficacy in HF and their potential synergistic utilization alongside sodium-glucose cotransporter 2 (SGLT2) inhibitors. The gene discussed is SLC5A2; the disease is hydrops fetalis.